Rett syndrome (RS) is a severe neurodevelopmental disorder caused mainly by pathogenic variants in the MECP2 gene, located on the X chromosome. Although it is transmitted in an X-linked dominant pattern, most cases appear de novo and mainly affect girls. The alteration of the MECP2 protein, an epigenetic regulator essential for neuron maturation and maintenance, causes a regression of motor and communication skills after an initial period of apparently normal development.
Rett syndrome
The MECP2 gene encodes the MECP2 protein, a protein abundant in the brain that binds to methylated regions of DNA and regulates the activity of numerous genes. This function is especially important in mature neurons, where it contributes to the maintenance of synapses, neuronal plasticity, and the balance of brain circuits. Therefore, MECP2 does not act as a single genetic switch, but as a broad regulator of gene expression and the functional organization of the nervous system. When pathogenic variants exist in MECP2, the MECP2 protein may be absent, truncated, or have an altered function. This dysfunction interferes with neuronal maturation and synaptic communication, leading to the characteristic phenotype of Rett syndrome. Inheritance is considered X-linked dominant, but most cases are sporadic. In females, severity can vary due to X chromosome inactivation patterns and variant type; in males, the spectrum is broader than classically described and includes from severe neonatal encephalopathy to X-linked intellectual disability or forms compatible with Rett in cases of mosaicism or karyotypes with an additional X chromosome. The incidence is estimated at approximately 1 in every 10,000 to 23,000 live-born girls.
Symptoms
The onset usually occurs after a seemingly normal initial development, with a phase of stagnation and regression between 6 and 18 months of age. Characteristic signs include loss of intentional hand use, onset of repetitive hand-washing-like movements, partial or complete loss of acquired language, apraxia, gait disturbance, initial hypotonia, and deceleration of head growth. Epilepsy, respiratory abnormalities, sleep disorders, constipation, gastroesophageal reflux, scoliosis, nutritional problems, and autonomic alterations are also common. The clinical course is variable, and classical and atypical forms exist.
Disease management
The management of Rett syndrome is multidisciplinary and focuses on maintaining function, preventing complications, and improving quality of life. It includes physiotherapy, occupational therapy, speech therapy, augmentative communication systems, nutritional support, scoliosis surveillance, treatment of epilepsy, sleep, gastrointestinal symptoms, and respiratory problems, as well as cardiological follow-up when there is a risk of QT interval prolongation. There is no cure that reverses the genetic alteration. Trofinetide is approved in some countries for the treatment of central Rett syndrome symptoms in pediatric and adult patients, although it is not curative and its availability depends on the regulatory context. Genetic counseling is important, as the risk of recurrence is usually low in de novo cases, but it can increase if there is germline mosaicism or a carrier mother.
Genes analyzed
Bibliography
Gold WA, Percy AK, Neul JL, et al. Rett syndrome. Nat Rev Dis Primers. 2024 Nov 7;10(1):84. Erratum in: Nat Rev Dis Primers. 2025 Mar 24;11(1):19.
Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018 Feb;8(2):170216.
Choi G, Lee S, Yoo S, et al. MECP2 Dysfunction in Rett Syndrome: Molecular Mechanisms, Multisystem Pathology, and Emerging Therapeutic Strategies. Int J Mol Sci. 2025 Aug 26;26(17):8277.
Liu Y, Whitfield TW, Bell GW, et al. Exploring the complexity of MECP2 function in Rett syndrome. Nat Rev Neurosci. 2025 Jul;26(7):379-398. Epub 2025 May 13.
